Investigation of a Congenital Abnormal Plasminogen, Frankfurt I, and Its Relationship to Thrombosis

Summary

A new abnormal plasminogen, Frankfurt I, has been identified in the plasma of a 42 year-old male patient who has recurrent deep vein thrombosis. Clinical laboratory data showed normal hemostasis test results. Since plasma plasmin generation rates gave low values, the fibrinolytic system was analyzed for a possible fibrinolytic system defect. Functional and antigen plasminogen concentrations both in the plasma and with the isolated, purified plasminogen showed that only 49% of the antigen concentration had potential functional active sites. Also, a reduced antigen concentration was found in both the propositus, and his mother (46% active sites).

Sodium dodecyl sulfate polyacrylamide gel electrophoresis of the purified Frankfurt I plasminogen showed a normal native Glu-plasminogen band. Crossed-immunoelectrophoresis revealed a peak with normal size and shape, but displaced with respect to normal Glu-plasminogen toward the anode, i. e., was, as a whole, more negatively charged. Isoelectric focusing followed by zymog-raphy on a agarose-fibrin plate proved this observation, but did not indicate a separation of the normal from the abnormal plasminogen molecular species, also, fewer bands were found in the abnormal plasminogen isozyme pattern.

Kinetic studies of Frankfurt I Glu-plasminogen and plasmin led to the conclusion that most of the functional abnormality is related to absence of active sites in half of the molecules. The plasmin generated was very unstable in the absence of stabilizing ligands and/or substrates. After reduction, the plasmin was completely converted to the typical two plasmin chains, A and B.

Keywords

Abnormal plasminogens - Variant plasminogen Frankfurt I - Deep vein thrombosis - Fibrinolysis

• References

• 1 Aoki N, Moroi M, Sakata Y, Yoshida N, Matsuda M. Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest 1978; 61: 1186-1195
• 2 Miyata T, Iwanaga S, Sakata Y, Aoki N. Plasminogen Tochigi: Inactive plasmin from replacement of alanine-600 by threonine in the active site. Proc Natl Acad Sci USA 1982; 79: 6132-6136
• 3 Miyata T, Iwanaga S, Sakata Y, Aoki N, Takamatsu J, Kamiya T. Plasminogen Tochigi II and Nagoya. Two additional molecular defects with Ala-600-Thr replacement found in plasmin light chain variants. J Biochem 1984; 96: 277-287
• 4 Kazama M, Tahara C, Suzuki Z, Gohchi K, Abe T. Abnormal plasminogen, a case of recurrent thrombosis. Thromb Res 1981; 21: 517-522
• 5 Soria J, Soria C, Bertrand O, Dunn F, Drouet L, Caen JP. Plasminogen Paris I: Congenital abnormal plasminogen and its incidence to thrombosis. Thromb Res 1983; 32: 229-238
• 6 Wohl RC, Summaria L, Robbins KC. Physiological activation of the human fibrinolytic system. Isolation and characterization of human plasminogen variants, Chicago I and Chicago II. J Biol Chem 1979; 254: 9063-9069
• 7 Wohl RC, Summaria L, Chediak J, Rosenfeld S, Robbins KC. Human plasminogen variant Chicago III. Thromb Haemostas 1982; 48: 146-152
• 8 Sakata Y, Aoki N. Molecular abnormality of plasminogen. J Biol Chem 1980; 255: 5442-5447
• 9 Aoki N, Tateno K, Sakata Y. Differences of frequency distribution of plasminogen phenotypes between Japanese and American populations: New methods for the detection of plasminogen variants. Biochem Genet 1984; 22: 871-881
• 10 Wohl RC, Sinio L, Robbins KC. Methods for studying fibrinolytic pathway components in human plasma. Thromb Res 1982; 27: 523-535
• 11 Porath J, Birgit O. Immobilized metal ion affinity adsorption and immobilized metal ion affinity chromatography by biomaterials. Serum protein affinities for gel immobilized iron and nickel ions. Biochemistry 1983; 22: 1621-1630
• 12 Sumi H, Sasaki K, Muramutu M. A simple and rapid purification method of urokinase using a [Na-(ɛ-aminocaproyl)-DL-homoarginine hexylester]-Sepharose column. Acta Haemat Jap 1978; 41: 766-770
• 13 Robbins KC, Summaria L. Plasminogen and Plasmin. Meth Enzymol 1976; 45: 257-273
• 14 Summaria L, Arzadon L, Bemabe P, Robbins KC. The activation of plasminogen to plasmin by urokinase in the presence of the plasmin inhibitor Trasylol. The preparation of plasmin with the same NH₂-terminal heavy (A) chain sequence as the parent zymogen. J Biol Chem 1975; 250: 3988-3995
• 15 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
• 16 Axelsen NH, Kroll J, Weeke B. A manual of qualitative immunoelectrophoresis methods and applications. Scand J. Immunol 1973; 2 (Suppl. 01) 169
• 17 Kostulas VK, Link H. Agarose isoelectric focusing of unconcentrated CSF and radioimmuno-fixation for detection of oligoclonal bands in patients with multiple sclerosis and other neurological diseases. J Neurol Sci 1982; 54: 117-127
• 18 Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234
• 19 Chase Jr T, Shaw E. Comparison of the esterase activities of trypsin, plasmin and thrombin on guanidinobenzoate esters. Titration of the enzymes. Biochemistry 1969; 8: 2212-2224
• 20 Wohl RC, Summaria L, Robbins KC. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37° C. J Biol Chem 1980; 255: 2005-2013
• 21 Wohl RC, Sinio L, Summaria L, Robbins KC. Comparative activation kinetics of mammalian plasminogens. Biochim Biophys Acta 1983; 754: 20-31
• 22 Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-145
• 23 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat 1957; 17: 237-246
• 24 Procter RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Amer J Clin Path 1961; 36: 212-219
• 25 Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Wille-brand’s disease. J Clin Invest 1971; 50: 244-254
• 26 Bull BS, Schneidermann MA, Brecher G. Platelet counts with the Coulter Counter. Amer J Clin Path 1965; 44: 678-688
• 27 Amiral J. Determination of protein C by an immunoenzymatic assay. In: Protein C - Biochemical and Medical Aspects. GlickWitt I. (ed.) 67-75 Walter de Gruyter; Berlin: 1985
• 28 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haemat 1981; 10: 369-390
• 29 Gallimore MJ, Amundsen E, Assen AO, Larsbraaten M, Lyngaas K, Svendsen L. Studies on plasma antiplasmin activity using a new plasmin specific chromogenic tripeptide substrate. Thromb Res 1979; 14: 51-60
• 30 Becker W, Rapp W, Schwick HG, Storiko K. Methoden zur quantitativen Bestimmung von Plasmaproteinen durch Immunprazipi-tation. Z Klin Chem Klin Biochem 1968; 3: 113-122
• 31 Brakman P. Fibrinolysis. A standardized fibrin plate method and a fibrinolytic assay of plasminogen. Scheltema and Holkema; Amsterdam: 1967
• 32 Hach V, Heyland H, Walter-Fincke R, Scharrer I. Verminderte fibrinolytische Aktivitat in Venenwanden von Patienten mit venosen Thrombosen. VASA 1985; 14: 336